Table 3 Univariate logistic regression analysis for association between treatment variables and overall grade ≥ 3 toxicity
Characteristic | Control (n = 61) n (%) | Case (n = 32) n (%) | OR [95% CI] | p-value |
|---|---|---|---|---|
Chemotherapy regimen | ||||
 Adjuvant | 19 (31.1) | 7 (21.9) | Ref. | 0.21 |
 Peri-operative | 16 (26.2) | 16 (50) | 2.71 (0.91–8.62) |  |
 Palliative | 22 (36.1) | 8 (25) | 0.98 (0.29–3.30) |  |
 CMT + RDT Adjuvant | 3 (4.9) | 1 (3.1) | 0.90 (0.04–8.52) |  |
 CMT + RDT Peri-operative | 1 (1.6) | 0 | NA |  |
Chemotherapy scheme | ||||
 FOLFOX | 29 (47.5) | 17 (53.1) | Ref. | 0.07 |
 CAPEOX | 12 (19.7) | 5 (15.6) | 0.71 (0.19–1.05) |  |
 CF | 7 (11.5) | 6 (18.8) | 1.46 (0.40–5.12) |  |
 DCFm | 5 (8.2) | 0 | NA |  |
 ECF | 0 | 2 (6.3) | NA |  |
 EOX | 2 (3.3) | 0 | NA |  |
 Capecitabine | 2 (3.3) | 0 | NA |  |
 FLOT | 0 | 1 (3.1) | NA |  |
 RDT + 5-FU/Leu | 2 (3.3) | 1 (3.1) | 0.85 (0.03–9.55) |  |
 RDT + CAPEOX | 1 (1.6) | 0 | NA |  |
 RDT + Cis/Cape | 1 (1.6) | 0 | NA |  |
Previously treated | ||||
 No | 53 (86.9) | 30 (93.7) | Ref. |  |
 Yes | 8 (13.1) | 2 (6.3) | 0.44 (0.06–1.90) | 0.29 |
Scheme contains | ||||
 RDT | 4 (6.6) | 1 (3.1) | 0.45 (0.02–3.27) | 0.46 |
 5-FU | 43 (70.5) | 27 (84.4) | 2.26 (0.79–7.48) | 0.12 |
 Capecitabine | 16 (26.2) | 5 (15.6) | 0.52 (0.15–1.50) | 0.23 |
 Oxaliplatin | 44 (72.1) | 23 (71.9) | 0.81 (0.30–2.21) | 0.67 |
 Cisplatin | 13 (21.3) | 8 (25.0) | 1.23 (0.43–3.33) | 0.68 |
 Docetaxel | 5 (8.2) | 1 (3.1) | 0.36 (0.01–2.37) | 0.31 |